Zeposia

(ozanimod)
ozanimod 0.23 MG Oral Capsule [Zeposia]ozanimod 0.46 MG Oral Capsule [Zeposia]
View 1 more
NO BOXED WARNING

Dosage & administration

drug label

Zeposia prescribing information

prior authorization

Zeposia prior authorization resources

Most recent Zeposia prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medical Injectable Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Outpatient Chemotherapy Prior Authorization Form (Medical Benefit)
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Jan 28, 2024Oregon - Uniform Prior Authorization Form
Verified: Jan 28, 2024Colorado - Uniform Prior Authorization Form
Verified: Jan 28, 2024Michigan - Uniform Prior Authorization Form
Verified: Jan 28, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jan 28, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jan 28, 2024Texas - Uniform Prior Authorization Form
Verified: Jan 28, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Arizona - Uniform Prior Authorization Form
Verified: Jan 28, 2024Indiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Illinois - Uniform Prior Authorization Form
Coverage Authorization Request: Multiple Sclerosis
Letter of Appeal for Patients Currently Receiving MS Treatment
Letter of Appeal for Patients Not Currently Receiving MS Treatment
Letter for Medical Necessity for Patients Currently Receiving MS Treatment
Letter for Medical Necessity for Patients Not Currently Receiving MS Treatment
Formulary Exception Letter: Multiple Sclerosis
Appeals & Authorizations Kit: Multiple Sclerosis
Coverage Authorization Request: Ulcerative Colitis
Coverage Authorization Appeals: Ulcerative Colitis
Letter of Medical Necessity: Ulcerative Colitis
Authorization & Appeals Kit: Ulcerative Colitis
Learn More

Benefits investigation

Zeposia Start Form: Ulcerative Colitis
Zeposia Start Form: Multiple Sclerosis
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

pharmacy

Zeposia preferred pharmacy

Pharmacy List

Financial Assistance

Financial Assistance Programs

Zeposia retails for $8,840 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Zeposia for significantly less. Review the program information below to determine what program can offer your patient the most benefits.
CoPay Card Program$0 Co Pay
Available for
commercial
Program Details
  • $313 for Capsule
Forms
Zeposia Start Form: Ulcerative Colitis
Zeposia Start Form: Multiple Sclerosis
Enroll in Patient Savings Program: Ulcerative Colitis
Enroll in Patient Savings Program: Multiple Sclerosis
Patient Assistance Program30 days supply for as low as $0
Available for
commercial
Program Details
  • Program Expires 12/31/23
  • $ Annual Cap
Forms
Zeposia Start Form: Ulcerative Colitis
Zeposia Start Form: Multiple Sclerosis
Enroll in Patient Savings Program: Ulcerative Colitis
Enroll in Patient Savings Program: Multiple Sclerosis

PubMed™ | Zeposia

Zeposia PubMed™ News

patient education

Zeposia patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Zeposia: Ulcerative Colitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Zeposia: Ulcerative Colitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects: Ulcerative Colitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories: Ulcerative Colitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: Ulcerative Colitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide: Ulcerative Colitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Ulcerative Colitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Zeposia: Multiple Sclerosis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Zeposia: Multiple Sclerosis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects: Multiple Sclerosis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories: Multiple Sclerosis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: Multiple Sclerosis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Care Partner Resources: Multiple Sclerosis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Multiple Sclerosis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure (Spanish): Multiple Sclerosis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide: Multiple Sclerosis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Zeposia FAQs

What is the Pregnancy Exposure Registry for ZEPOSIA?The pregnancy exposure registry is a program that monitors pregnancy outcomes in women exposed to ZEPOSIA during pregnancy. Pregnant women can register themselves at www.zeposiapregnancyregistry.com or by calling 1-877-301-9314.
What is the Risk Summary for ZEPOSIA use in pregnancy?There are no adequate data on the developmental risk associated with the use of ZEPOSIA in pregnant women. In animal studies, administration of ozanimod during pregnancy produced adverse effects on development, including embryolethality, an increase in fetal malformations, and neurobehavioral changes, in the absence of maternal toxicity.
What are the risks of birth defects and miscarriage in women taking ZEPOSIA during pregnancy?The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies in the general population is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.
What are the animal data regarding ZEPOSIA use in pregnancy?In animal studies, oral administration of ozanimod during pregnancy resulted in a marked increase in embryofetal mortality, increased fetal malformations and skeletal variations, and reduced fetal body weight at the highest dose tested. Fetal blood vessel malformations occurred at clinically relevant maternal ozanimod and metabolite exposures in rabbits.
What is the Risk Summary for ZEPOSIA use during lactation?There are no data on the presence of ozanimod in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Following oral administration of ozanimod, ozanimod and/or metabolites were detected in the milk of lactating rat at levels higher than those in maternal plasma.
What should women of childbearing potential know before taking ZEPOSIA?Before initiation of ZEPOSIA treatment, women of childbearing potential should be counseled on the potential for a serious risk to the fetus and the need for contraception during treatment with ZEPOSIA. The potential risk to the fetus may persist for 3 months after stopping ZEPOSIA, so effective contraception should also be used during this time.
Is ZEPOSIA safe and effective for pediatric use?Safety and effectiveness of ZEPOSIA in pediatric patients have not been established.
Were elderly patients included in clinical studies of ZEPOSIA?No, clinical studies of ZEPOSIA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Are there any age-related differences in the pharmacokinetics of ZEPOSIA?No clinically significant differences in the pharmacokinetics of ozanimod and CC112273 were observed based on age.
Should elderly patients be monitored for any adverse reactions to ZEPOSIA?Yes, elderly patients should be monitored for cardiac and hepatic adverse reactions, because of the greater frequency of reduced cardiac and hepatic function in the elderly population.
Is it recommended to use ZEPOSIA in patients with hepatic impairment?No, the use of ZEPOSIA in patients with hepatic impairment is not recommended because the effect of hepatic impairment on the pharmacokinetics of the ozanimod major active metabolites is unknown.
FAQ Data Source